Rush University Cancer Center — Chicago, Illinois

Rush University Cancer Center is a clinical research site located in Chicago, Illinois, United States 60612.

Crixeo Health Trust Score: 78/100 (FAIR). This profile has not yet been claimed by the site owner.

Rush University Cancer Center has participated in 11 clinical trials with 4 currently active.

Therapeutic areas: Acute Myeloid Leukemia, Prostate Cancer, Breast Cancer.

Sponsors: Sellas Life Sciences Group, BioProtect, Stemline Therapeutics, Inc..

Sponsor Feasibility Report

Trust Score: 78/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Rush University Cancer Center?

Rush University Cancer Center has a Crixeo Trust Score of 78/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Rush University Cancer Center conducted?

Rush University Cancer Center has 11 clinical trials on record, with 4 currently active. Their work covers Acute Myeloid Leukemia, Prostate Cancer, Breast Cancer.

Is Rush University Cancer Center accredited by Crixeo Health?

Yes — Rush University Cancer Center holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Rush University Cancer Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.